Large-cap Health Care company United Therapeutics has logged a -1.3% change today on a trading volume of 555,432. The average volume for the stock is 483,971.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Based in Silver Spring, United States the company has 1,400 full time employees and a market cap of $22,571,655,168.
The company is now trading -20.03% away from its average analyst target price of $658.08 per share. The 13 analysts following the stock have set target prices ranging from $515.0 to $750.0, and on average give United Therapeutics a rating of buy.
Over the last 52 weeks, UTHR stock has risen 71.2%, which amounts to a 52.3% difference compared to the S&P 500. The stock's 52 week high is $609.35 whereas its 52 week low is $292.34 per share. Based on United Therapeutics's average net margin growth of 3.1% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2025 | 3,182,700 | 1,334,700 | 42 | 0.0 |
| 2024 | 2,877,400 | 1,195,100 | 42 | 0.0 |
| 2023 | 2,327,500 | 984,800 | 42 | 10.53 |
| 2022 | 1,936,300 | 727,300 | 38 | 35.71 |
| 2021 | 1,685,500 | 475,800 | 28 | -20.0 |
| 2020 | 1,483,300 | 514,800 | 35 |
